Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1997; 76(8): 1055–1061.
PMCID: PMC2228081

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.


In 1983, Coates conducted a survey that ranked the side-effects perceived by patients receiving chemotherapy in the order of their severity. Vomiting and nausea were found to be the two most distressing side-effects. They have an impact on quality of life and compliance with treatment. The development of 5HT3 antagonists has been a major step forward in the prevention and treatment of chemotherapy-induced nausea and vomiting. Presently, these antiemetics are routinely used as concomitant therapy in emetogenic chemotherapy regimens. The purpose of this study was to evaluate the impact of 5HT3 antagonists on patient perceptions of the side-effects of chemotherapy. Coates' survey was replicated in patients who received 5HT3 antagonists for acute nausea and vomiting resulting from emetogenic chemotherapy. Patients received the survey to identify those physical and non-physical side-effects that they attributed to chemotherapy and were asked to rank the five most distressing side-effects. Of the 197 patients who consented to take part in the study, 181 were evaluable. Nausea, hair loss and vomiting were described as the three most distressing side-effects of chemotherapy. Eighty per cent of all the patients actually experienced nausea and 57% experienced vomiting. Hair loss appeared to be more distressing to women (P < 0.001) but, in other aspects, gender, age and marital status did not influence the ranking of the three most distressing side-effects. Constipation was ranked as 6th and was not identified as a distressing side-effect in 1983. Nausea and vomiting remain to be the first and third most distressing side-effects of chemotherapy, even though the incidence and severity of acute nausea and vomiting are now significantly reduced.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1017K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bliss JM, Robertson B, Selby PJ. The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl. 1992 Dec;19:S14–S23. [PubMed]
  • Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983 Feb;19(2):203–208. [PubMed]
  • Cooper S, Georgiou V. The impact of cytotoxic chemotherapy--perspectives from patients, specialists and nurses. Eur J Cancer. 1992;28A Suppl 1:S36–S38. [PubMed]
  • Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE. Fertility after chemotherapy for testicular cancer. J Clin Oncol. 1983 Mar;1(3):179–183. [PubMed]
  • Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996 Feb;7(2):189–195. [PubMed]
  • Jansen C, Halliburton P, Dibble S, Dodd MJ. Family problems during cancer chemotherapy. Oncol Nurs Forum. 1993 May;20(4):689–696. [PubMed]
  • Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer. 1989 Feb 1;63(3):604–612. [PubMed]
  • Manson H, Manderino MA, Johnson MH. Chemotherapy: thoughts and images of patients with cancer. Oncol Nurs Forum. 1993 Apr;20(3):527–532. [PubMed]
  • Martin M. Myths and realities of antiemetic treatment. Br J Cancer Suppl. 1992 Dec;19:S46–S53. [PubMed]
  • Schmoll HJ. Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper. Br J Cancer Suppl. 1992 Dec;19:S24–S25. [PubMed]
  • de Wit R, Schmitz PI, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS, van der Burg ME, Stoter G. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol. 1996 Feb;14(2):644–651. [PubMed]
  • Youngblood M, Williams PD, Eyles H, Waring J, Runyon S. A comparison of two methods of assessing cancer therapy-related symptoms. Cancer Nurs. 1994 Feb;17(1):37–44. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK